Oral Cancer Treatment Companies

Alnylam Pharmaceuticals Positive topline results from Phase 3 ENVISION study of givosiran, an RNAi therapeutic for acute hepatic porphyria (including some oral cancer cases).Givosiran granted Breakthrough Therapy Designation by the US FDA for AIP.Ongoing Phase 3 ENVISION2 study of givosiran for oral cancer prevention.

Apellis Pharmaceuticals Developing APL-1202, a pegylated hemin product to manage acute porphyria attacks, potentially applicable to oral cancer.Phase 2b study of APL-1202 ongoing, with results expected in 2024.

Akcea Therapeutics Marketing Lumitrio (givosiran) for acute hepatic porphyria in the US and Europe, which may have some overlap with oral cancer.Expanding access to Lumitrio through patient assistance programs and collaborations with healthcare providers.

BioMarin Pharmaceutical Marketing Vyndaqel (tabeleumac) for hereditary transthyretin-mediated amyloidosis (hATTR), which can have some overlapping symptoms with oral cancer.Continuing research and development efforts for other rare diseases, including some oral cancers.

Merck KGaA:Keytruda (pembrolizumab) approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), which includes some oral cancers.Ongoing clinical trials of Keytruda in combination with other therapies for HNSCC.

List of Oral Cancer Treatment Key Companies in the Market

• Bristol-Myers Squibb Company (the U.S.)


• Qilu Pharmaceutical Co., Ltd. (Asia Pacific)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Eli Lilly and Company. (U.S.)


• F Hoffmann-La Roche Ltd (Europe)


• Merck & Co., Inc. (U.S.)


• Novartis AG (Europe)


• Pfizer Inc. (U.S.)